Application for pricey gene therapy Zolgensma contained manipulated data, but drug will remain on market, FDA says

Image: Shutterstock

The Food and Drug Administration said Tuesday [August 7]  that Novartis submitted manipulated data as part of its application for a new gene therapy, and didn’t tell the agency until after the treatment was approved.

Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said the inaccurate information involved mouse data and was a “small amount of the totality” that was submitted. The faulty data didn’t raise concerns about the safety and effectiveness of the treatment, he said, adding that the therapy will remain on the market.

The $2.1 million treatment — considered the world’s most expensive therapy — is called Zolgensma. It is used for children less than 2-years-old with spinal muscular atrophy, a leading genetic cause of infant death.


In a statement, Novartis said it is “fully confident in the safety, quality and efficacy of Zolgensma.” The drugmaker said AveXis investigated allegations of data manipulation and “once we had interim conclusions from our investigations, we shared our findings with the FDA.” The data, the company added, “are limited to an older process no longer in use.”

Related article:  Wanted: Volunteers willing to risk getting sick from the coronavirus for the greater good

Read full, original post: FDA: Gene therapy maker submitted manipulated data before drug was approved

Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Here’s where GM crops are grown around the world today

Infographic: Here’s where GM crops are grown around the world today

Do you know where biotech crops are grown in the world? This updated ISAAA infographics show where biotech crops were ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

* indicates required
Email Lists
Send this to a friend